Abbott's troponin test for Architect systems:
This article was originally published in Clinica
Abbott Laboratories has received US FDA 510(k) clearance to run a test for the cardiac marker troponin I on its Architect line of immunoassay and immunochemistry analysers, the i2000SR and ci8200, respectively. The test marks the second assay in Abbott's acute cardiac panel for the Architect platform, says the Abbott Park, Illinois firm, which is developing additional cardiac assays. It is already available in major markets outside the US. The company added that based on the American College of Cardiology's new criteria for diagnosing heart attack, troponin has become the gold standard in diagnostic testing.
You may also be interested in...
Guidelines outline permitted practices and patient safeguards for both physicians and technology platforms.
Executives at Pfizer and Moderna expressed confidence in their US government partners for initial COVID-19 vaccine distribution and expect pediatric studies to begin before the end of the year. Regeneron will “do the right thing” in pricing its antibody cocktail.
Takeda's acquisition of Shire fueled the company into a top 10 pharma company in the latest Scrip 100 rankings, as other mega-mergers are set to shape the leaderboard in the future.